Hims & Hers Health shares slump over 9% as acute selling pressure drives price below short-term support

Traders Union
All News
Financial News
Hims & hers health slides 9.34% today

Highlights

Hims & Hers Health was upgraded to 'hold' from 'strong sell' by Zacks Research, reflecting less bearish sentiment.
Investor accumulation patterns emerge in the stock despite ongoing broad market selling pressure on medical-service names.
Short-term selling persists, but technical indicators favor buyers with an 80% likelihood of an upward move into a $31.53–$35.78 range.

Investor accumulation persists as rating downgrade prompts cautious trading

Hims & Hers Health was recently upgraded from a 'strong sell' to a 'hold' rating according to Zacks Research. The company was also noted for ongoing accumulation patterns and was discussed in the context of income trading strategies. Reports placed it among medical-services stocks showing investor interest, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes that despite signaled accumulation and an analyst upgrade, Hims & Hers Health shows acute short-term technical weakness. He highlights that the recent drop below the 20-day moving average and the downside gap reflect a lack of sustained buyer conviction and elevated risk. Kharitonov remains wary of the overbought readings and the market’s dependence on favorable momentum, pointing out inherent fragility in the stock's setup. He cautions that, while medium- and long-term technical support are noted, the persistent selling pressure may expose the stock to sharper corrections if sentiment sours further. "Unless we see renewed institutional interest and stability above $34.71, I consider the recent upgrade insufficient for a sustained turnaround."

Viktoras Karapetjanc, expert at Traders Union, sees strong undercurrents of investor interest in Hims & Hers Health, as reflected by recent accumulation and an upgrade to 'hold'. He believes the bullish structure remains intact, with medium- and long-term averages supporting further upside. Karapetjanc considers the recent downside move as a tactical opportunity for active traders, especially with buyers dominating intraday momentum and a very high probability of rebound. He is confident the market offers multiple setups for continuation higher if short-term resistance is overcome. "With improving sentiment and structural support in place, I expect further growth toward the upper end of the $31.53–$35.78 range."

Jainam Mehta, market strategist, points out that HIMS is caught between short-term selling and longer-term support, creating tactical ambiguity. He sees potential for a contrarian entry given mixed momentum signals and a recent upgrade, but stresses the need for confirmation above near-term resistance. Mehta notes that if the price holds above the Kijun support, a breakout could follow. "If we see a momentum reversal and reclaim of $33.86, I would look for a tactical long setup with a stop just below $33.29."

Short-term weakness persists despite longer-term technical support and mixed momentum

Hims & Hers Health is trading below its 20-day moving average ($34.71), but remains above both the 50-day ($29.58) and 200-day ($31.91) moving averages, indicating short-term selling pressure but continued support from longer-term trends. The Ichimoku Kijun ($32.5) serves as support, with a near-term resistance at $33.86 and a near-term floor at $33.29. Momentum indicators give a mixed yet generally supportive picture: the MACD and ADX show buy signals, the RSI stands at 63.29 with a buy outlook, and the CCI is also positive. The Bull/Bear Power at 2.32 suggests buyers have dominated intraday momentum, yet the overbought forecast flags stretched short-term conditions. The price has dropped near session lows, aligning with strong selling pressure throughout the day despite favorable overall momentum signals.

Earlier, analysts noted that Hims & Hers Health faced short-term technical pressures while retaining a constructive longer-term trend outlook. With the stock experiencing heightened selling despite analyst upgrades and ongoing accumulation, investors should monitor for a potential shift in momentum if trading volumes spike or the price decisively breaks above near-term resistance.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.